The new platform provides a continuous pathway for cytotoxic payloads and targeted oncology treatments, offering capabilities that range from milligram-scale synthesis to commercial-ready batches. With a designed annual capacity of 500-600 kg of active pharmaceutical ingredients, the facility utilizes advanced containment technology capable of managing compounds with occupational exposure limits as low as 10 ng/m³.

Chief Executive Officer of Small Molecules-CDMO Aniel Khubchandani noted that the integration minimizes handoffs between providers, ensuring that process knowledge remains intact as drug candidates move toward commercialization. This consolidation of discovery and cGMP production sets the stage for the company to expand into advanced modalities, specifically antibody-drug and peptide-drug conjugates. Aragen, which counts 16 of the world’s top 20 pharmaceutical companies among its 591 global clients, maintains a robust regulatory footprint with accreditations from the USFDA, EDQM, and other international health authorities.